Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Jon C. Ogg | Apr 1, 2014 at 2:10 PM EDT

Will Prana’s Implosion Go All the Way?

ThinkstockThe first question anyone might ask if a stock falls from more than $9 to less than $2.50 is whether…

Trey Thoelcke | Mar 31, 2014 at 12:50 PM EDT

Teva’s Latest Victory in Effort to Protect Key Patents

Teva Pharmaceutical shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to…

Paul Ausick | Mar 31, 2014 at 8:20 AM EDT

Biotech Firm Prana Misses Goal on Alzheimer Drug

Prana Biotechnology announced Monday morning that top-line results for a Phase II trial of its Alzheimer drug failed to meet…

Jon C. Ogg | Mar 27, 2014 at 9:15 AM EDT

Baxter Split-Up, a Page From Abbott’s Playbook

Baxter International is taking an activist investor role of its own. The health care company has announced that it is…

Jon C. Ogg | Mar 27, 2014 at 8:55 AM EDT

Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks

courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley…

Jon C. Ogg | Mar 26, 2014 at 1:45 PM EDT

Medicare Reimbursement Relief for Lab Testing, Maybe

ThinkstockThe House of Representatives may be single-handedly saving the lab companies in America on Wednesday. A bill was posted to…

Jon C. Ogg | Mar 26, 2014 at 12:05 PM EDT

Exelixis Enters the Danger Zone

Exelixis may have a while longer before it gets to be a serious revenue stage company. Its stock was crushed…

Trey Thoelcke | Mar 26, 2014 at 8:45 AM EDT

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large…

Paul Ausick | Mar 26, 2014 at 8:20 AM EDT

Insmed Joins Biotech Trash Heap

When a drug trial goes bad, the hit to a drug maker's stock is instant and spectacular. Wednesday it will…

Trey Thoelcke | Mar 26, 2014 at 7:25 AM EDT

Short Sellers Find Renewed Interest in Biotech Stocks

After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early…

Trey Thoelcke | Mar 24, 2014 at 9:55 AM EDT

Top Biotechnology Stocks On Sale Again

For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from…

Jon C. Ogg | Mar 21, 2014 at 1:00 PM EDT

Zogenix CEO Goes on the Offensive

Zogenix has traded like a company that is about to implode. Its highly controversial Zohydro has been getting inquiries into…

Paul Ausick | Mar 21, 2014 at 12:15 PM EDT

Biopharma Firm Versartis Gets Golden IPO Treatment

Biopharmaceutical firm Versartis sold 6 million shares in a Friday morning IPO at a price higher than the estimated range.…

Jon C. Ogg | Mar 21, 2014 at 10:30 AM EDT

Did Endocyte Just Become Buyout Bait?

Endocyte is trading like it is being acquired. This is proof that any biotech with great cancer drug news can…

Paul Ausick | Mar 21, 2014 at 9:05 AM EDT

Could Obamacare Be Working?

WellPoint raised its earnings outlook for the 2014 fiscal year, citing a benefit from the Affordable Care Act, aka Obamacare,…

1 … 290 291 292 293 294 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Will Prana’s Implosion Go All the Way?

Teva’s Latest Victory in Effort to Protect Key Patents

Biotech Firm Prana Misses Goal on Alzheimer Drug

Baxter Split-Up, a Page From Abbott’s Playbook

Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks

Medicare Reimbursement Relief for Lab Testing, Maybe

Exelixis Enters the Danger Zone

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

Insmed Joins Biotech Trash Heap

Short Sellers Find Renewed Interest in Biotech Stocks

Top Biotechnology Stocks On Sale Again

Zogenix CEO Goes on the Offensive

Biopharma Firm Versartis Gets Golden IPO Treatment

Did Endocyte Just Become Buyout Bait?

Could Obamacare Be Working?

Wall Street is Braced for Massive Inflation Numbers Wednesday Morning. Here’s What Numbers Could Cause Stocks to Sink or Soar.

3 Robotics Stocks in the M&A Spotlight in 2026

Forget VOO: Fidelity’s Tech ETF Is Up 29% While the Broad Market Lags

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

Wall Street is Braced for Massive Inflation Numbers Wednesday Morning. Here’s What Numbers Could Cause Stocks to Sink or Soar.

3 Robotics Stocks in the M&A Spotlight in 2026

Health and Healthcare Articles

All Health and Healthcare Articles

Will Prana’s Implosion Go All the Way?

Teva’s Latest Victory in Effort to Protect Key Patents

Biotech Firm Prana Misses Goal on Alzheimer Drug

Baxter Split-Up, a Page From Abbott’s Playbook

Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks

Medicare Reimbursement Relief for Lab Testing, Maybe

Exelixis Enters the Danger Zone

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

Insmed Joins Biotech Trash Heap

Short Sellers Find Renewed Interest in Biotech Stocks

Top Biotechnology Stocks On Sale Again

Zogenix CEO Goes on the Offensive

Biopharma Firm Versartis Gets Golden IPO Treatment

Did Endocyte Just Become Buyout Bait?

Could Obamacare Be Working?

Wall Street is Braced for Massive Inflation Numbers Wednesday Morning. Here’s What Numbers Could Cause Stocks to Sink or Soar.

3 Robotics Stocks in the M&A Spotlight in 2026

Forget VOO: Fidelity’s Tech ETF Is Up 29% While the Broad Market Lags

Featured Reads

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year